The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA Peptide Reclassification 2026: What It Means for Providers The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype Is BPC 157 Legal? Understanding Its Status and Implications Peptides, Drugs And Supplements: Science, Risks, And Alternatives Los Angeles Times